课题基金 / 基金详情

MECHANISM OF ACTIVATION OF LATENT TGF BETA BY VASCULAR E

MECHANISM OF ACTIVATION OF LATENT TGF BETA BY VASCULAR E
血管E激活潜伏TGFβ的机制
批准号:
2683409
负责人:
DANIEL B RIFKIN
金额:
$36.46万
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-02-01 至 2001-03-31

项目摘要

项目成果

DANIEL B RIFKIN的其他基金

相似基金

相关文献

中文摘要
翻译
细胞因子转化因子-β(TGF-β)是从细胞中释放出来的 一种非活性的复合体,由仍与其结合的活性分子组成 通过静电相互作用切割的前肽。此外,潜在的 转化生长因子-β蛋白(LTBP)是一种独立的基因产物,与 通过二硫键形成的前肽。尽管细胞产生潜伏的转化生长因子-β 从结构上讲,转化生长因子-β血管细胞的形成通常需要 两种不同细胞类型的相互作用,如内皮细胞和 平滑的肌肉细胞。激活也需要尿激酶的作用。 纤溶酶原激活物(UPA)、纤溶酶、组织II型谷氨酰胺转氨酶 (TGase),该络合物与细胞表面甘露糖6- 磷酸/IGF-II受体(M6P/IGF-IIR)和活性LTBP。每一位 异型对中的细胞似乎对特定的反应物有贡献 活化反应。这些分子以协同的方式作用于 由潜伏的转化生长因子-β形成转化生长因子-β的细胞表面或基质。我们 建议该反应将潜在的络合物集中在表面或 通过将潜伏的复合物结合到M6P/IGF-IIR上,然后交叉结合到M6P/IGF-IIR上形成基质. 通过TGase将LTBP连接到未知的基质或表面分子。 由尿激活酶形成的纤溶酶然后释放活性细胞因子 通过裂解前肽和破坏酶的稳定性来固定化结构 离子相互作用。 在本申请中,我们建议阐明 在分子水平上形成转化生长因子-β所需的特定成分 并建立这一机制的体内意义。首先,我们 将表征TGase与LTBP的相互作用。使用生物化学 和分子技术,我们将确定TGase在哪里反应 残基在LTBP中,LTBP与什么分子交联,以及 这种交联性对潜在的转化生长因子-β激活至关重要。后者 实验将检测LTBP的功能改变,使其反应 残留物不见了。我们还将研究纤溶酶对血管内皮细胞的作用。 并确定哪个键被纤溶酶切割,以及这是否 从潜伏的复合体中释放转化生长因子-β。第二,我们将建立 我们已确定为转化生长因子-β必需的各个步骤的顺序 队形。我们将利用有序的添加和撤回 反应中每一步的特定抑制剂,然后进行测量 由测试细胞产生的转化生长因子-β的序列 个人反应。第三,我们将检查在体内的意义 我们的体外实验结果显示,小鼠肺损伤模型依赖于 转化生长因子-β的形成。在这个模型中,肺中的失血性休克可以 通过注射转化生长因子-β1的中和抗体来预防。 我们将监测抑制TGase或TGase的药物的能力 抗LTBP、uPA和M6P/IGF-IIR抗体,当时给小鼠注射 以防止出现肺病理,如 组织学和生化方法。
英文摘要
The cytokine transforming factor-beta (TGF-beta) is released from cells as an inactive complex consisting of the active molecule still bound to its cleaved propeptide by electrostatic interactions. In addition, the latent TGF-beta protein (LTBP), a separate gene product, is linked to the propeptide by a disulfide bond. Although cells produce latent TGF-beta constitutively, formation of TGF-beta vascular cells normally requires the interaction of two different cell types such as endothelial cells and smooth muscle cells. Activation also requires the action of urokinase type plasminogen activator (uPA), plasmin, tissue type II transglutaminase (TGase), interaction of the complex with the cell surface mannose 6- phosphate/IGF-II receptor (M6P/IGF-IIr), and active LTBP. Each of the cells in a heterotypic pair appears to contribute specific reactants to the activation reaction. These molecules act in a concerted fashion on the cell surface or matrix to form TGF-beta from latent TGF-beta. We propose that this reaction focuses the latent complex on the surface or matrix by binding the latent complex to the M6P/IGF-IIr followed by cross- linking of the LTBP to an unknown matrix or surface molecule by TGase. Plasmin formed by urokinase then releases the active cytokine from the immobilized structure by cleaving the propeptide and destabilizing the ionic interactions. In this application we propose to elucidate the interactions of the specific components required for TGF-beta formation at a molecular level and to establish the in vivo significance of this mechanism. First, we will characterize the interaction of TGase with LTBP. Using biochemical and molecular techniques, we will establish where the TGase reactive residues are in LTBP, to what molecule LTBP is cross-linked, and whether this cross-linking is crucial for latent TGF-beta activation. This latter experiment will test the function of LTBP altered so that the reactive residue is missing. We will also examine the action of plasmin on the propeptide and establish which bond is cleaved by plasmin and whether this releases TGF-beta from the latent complex. Second, we will establish the order of the various steps we have identified as essential for TGF-beta formation. We will utilize the ordered addition and withdrawal of inhibitors specific for each step in the reaction followed by measurement of TGF-beta production by the test cells to place in sequence the individual reactions. Third, we will examine the in vivo significance of our in vitro results in a mouse lung injury model that is dependent upon TGF-beta formation. In this model hemorrhagic shock in the lung can be prevented by the administration of neutralizing antibodies to TGF-beta1. We will monitor the ability of agents that either inhibit TGase or antibodies to LTBP, uPA, and M6P/IGF-IIr, administered to mice at the time of injury, to prevent the appearance of lung pathology as measured by histological and biochemical approaches.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2019 Elastin, Elastic Fibers and Microfibrils Gordon Research Conference and Seminar
  • 批准号:
    9760801
  • 项目类别:
  • 资助金额:
    $1.5万
  • 财政年份:
    2019
  • 负责人:
    DANIEL B RIFKIN
  • 依托单位:
Core A-Administrative Core
Altered Mechanotransduction as a Therapeutic Target for Thoracic Aortic Aneurysm
Altered Mechanotransduction
海外基金